Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ayala Pharmaceuticals Inc (AYLA)

11.54   -1.12 (-8.85%) 10-31 16:16
Open: 12.19 Pre. Close: 12.66
High: 12.75 Low: 11.39
Volume: 2,033 Market Cap: 147M
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.833 - 12.956 12.956 - 13.031
Low: 12.255 - 12.418 12.418 - 12.517
Close: 11.37 - 11.611 11.611 - 11.757

Technical analysis

as of: 2020-10-30 4:28:57 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.85     One year: 15.83
Support: Support1: 11.36    Support2: 9.45
Resistance: Resistance1: 12.71    Resistance2: 13.55
Pivot: 12.78
Moving Average: MA(5): 12.72     MA(20): 12.63
MA(100): 11.90     MA(250):
MACD: MACD(12,26): 0.17     Signal(9): 0.30
Stochastic oscillator: %K(14,3): 40.52     %D(3): 62.85
RSI: RSI(14): 39.27
52-week: High: 16.25  Low: 8.62  Change(%): -23.2
Average Vol(K): 3-Month: 884  10-Days: 465

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AYLA has closed above bottom band by 3.7%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 18 Sep 2020
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020 - GlobeNewswire

Mon, 14 Sep 2020
Ayala Pharmaceuticals to Host Virtual KOL Event Reviewing Interim Data Presented at ESMO 2020 from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma - GlobeNewswire

Thu, 13 Aug 2020
Ayala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update - GlobeNewswire

Mon, 27 Jul 2020
Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R/M Adenoid Cystic Carcinoma at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 - GlobeNewswire

Wed, 10 Jun 2020
Why This Ayala Pharmaceuticals Analyst Is Bullish - Benzinga

Mon, 01 Jun 2020
Ayala Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 13
Shares Float (M) 4
% Held by Insiders
% Held by Institutions
Shares Short (K) 7
Shares Short P. Month (K) 7

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin -716.98
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth 22.7
Gross Profit (p.s.) 0.082
Sales Per Share 0.255
EBITDA (p.s.) -1.814
Qtrly Earnings Growth
Operating Cash Flow (M) -21
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 45.24
Price to Cash Flow -7.18

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.